Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10491971 | 1.00 | PTPN1 (0.46) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL10491974 | 1.00 | PTPN1 (0.46) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL2911447 | 0.96 | PTPN1 (0.47) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL3452846 | 0.96 | PTPN1 (0.47) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL12807944 | 0.96 | PTPN1 (0.47) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL5383452 | 0.90 | PTPN1 (0.48) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL15095567 | 0.90 | PTPN1 (0.48) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL8389850 | 0.90 | PTPN1 (0.48) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL5383449 | 0.90 | PTPN1 (0.48) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL8394442 | 0.90 | PTPN1 (0.48) | PTPN1USP2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | PTPN1 1326/4885USP2 1945/4885POLB 3287/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | PTPN1 1270/4885USP2 2504/4885POLB 2984/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | PTPN1 1258/4885USP2 1990/4885POLB 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.